Surmodics (SRDX)
(Delayed Data from NSDQ)
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
Here's Why You Should Hold Integer Holdings in Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.
Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up
by Zacks Equity Research
Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.
Omeros (OMER) Surges: Stock Moves 10.2% Higher
by Zacks Equity Research
Omeros (OMER) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Baxter Collaborates With Mayo Clinic to Open Renal Care Center
by Zacks Equity Research
Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.
Surmodics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.
Is Surmodics (SRDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SRDX) Outperforming Other Medical Stocks This Year?
Intuitive Surgical and InTouch Collaborate for IoMT Services
by Zacks Equity Research
Intuitive Surgical's (ISRG) IoMT likely to benefit patients; market prospects impressive.
3 Top Stocks From the Booming US Medical Products Industry
by Sreyoshi Mukherjee
The U.S. Medical Products industry is sturdy on solid focus on technological advancement.
GW Pharmaceuticals (GWPH) Catches Eye: Stock Jumps 5.9%
by Zacks Equity Research
GW Pharmaceuticals (GWPH) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Medical - Products Stock Outlook: Short-Term Pain Inevitable
by Zacks Equity Research
Near-term growth prospects of medical products are being questioned due to trade war apprehensions and President Trump's imposition of fresh tariffs on about $200 billion on Chinese imports.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
by Zacks Equity Research
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
Why Is SurModics (SRDX) Up 19.9% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries
by Zacks Equity Research
Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries
4 of the Best Efficient Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International
by Zacks Equity Research
Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International
4 Winning Stocks With Solid Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
SurModics (SRDX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 437.50% and 12.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Top Performing Stocks of the Best ETF of 1H2018
by Sweta Killa
Inside the top performing stocks of the top ETF of the first half of 2018.
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
by Zacks Equity Research
Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips
4 of the Best Efficient Stocks to Buy for Superb Returns
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Here's Why You Must Add Surmodics (SRDX) to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) efforts to improve research and development stature bode well.
SYK or SRDX: Which is a Better Medical Product Stock?
by Zacks Equity Research
Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.